View of ASSESSING THE LEADER TRIAL: UNDERSTANDING MYOCARDIAL INFARCTION SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS AND THE BENEFICIAL IMPACT OF LIRAGLUTIDE THERAPY.

Return to Article Details ASSESSING THE LEADER TRIAL: UNDERSTANDING MYOCARDIAL INFARCTION SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS AND THE BENEFICIAL IMPACT OF LIRAGLUTIDE THERAPY. Download Download PDF